Sickle cell disease Nicosan

Current Global Therapeutic Options for Sickle Cell Disease and the Development of Nicosan... 

In early tests of the drug, it was found to have no toxieity at high doses in rats and it delayed polymerization of hemoglobin S in vitro (24,25). Phase I and Phase II elinieal trials in Nigeria indicated that Nicosan was safe and significantly reduced the number of sickle cell disease associated crises experienced by the patients (10,26). 

A portion of each of the three different batches used for the HPLC analysis shown in Figure 3 was sent to the National Heart, Lung and Blood Institute Sickle Cell Disease Center at Children s Hospital of Philadelphia, Philadelphia, Pennsylvania for determination of the level of antisickling activity. In these experiments, a low concentration (0.05 mg/ml) of Nicosan product was incubated with SS cells for 1 hr instead of the normal 3-4 hrs so that any differences could be seen more clearly. The levels of anti-sickling activity of the 3 different batches were nearly identical (Figure 4). 

R. C. Pandey, P. Tripathi, R. Misra, P. N. Gillette, T. Asakura (2005) Status of NICOSAN (TM)/ HEMOXINI (TM), an extract of a mixture of plants, for the treatment of sickle cell disease (SCD). In Vitro Cellular Developmental Biology-Animal, 41, 24A-24A. 

---